Skip to main content
Educational comparison - not medical advice. This page compares two compounds for informational purposes. Neither is recommended as treatment. Any protocol decision is a conversation with your licensed healthcare provider.
Home/Peptides/Semaglutide vs Retatrutide
HEAD-TO-HEAD COMPARISON

Semaglutide vs Retatrutide

Users researching the investigational triple-agonist class vs established GLP-1 mono-therapy.

QUICK ANSWER

Semaglutide is a GLP-1 mono-agonist, FDA-approved. Retatrutide is a triple agonist (GLP-1 + GIP + glucagon), Phase 3, not yet FDA-approved. Key specs: Semaglutide (GLP-1, ~7 days, Subcutaneous (weekly)) vs Retatrutide (GLP-1, ~6 days, Subcutaneous (weekly)).

OPTION A
Semaglutide
Semaglutide (Ozempic / Wegovy)
FDA-approved GLP-1 receptor agonist with the largest clinical evidence base for weight and glycemic outcomes.
Full profile →
OPTION B
Retatrutide
Retatrutide (LY-3437943)
Investigational triple agonist (GLP-1 / GIP / glucagon) with the largest weight-loss effect of any compound yet reported in its class.
Full profile →
THE CORE DIFFERENCE

Semaglutide is a GLP-1 mono-agonist, FDA-approved. Retatrutide is a triple agonist (GLP-1 + GIP + glucagon), Phase 3, not yet FDA-approved. Retatrutide's Phase 2 data showed ~24% weight reduction at 48 weeks vs semaglutide's ~15% at 68 weeks (different trials, not head-to-head). The glucagon arm of retatrutide adds energy-expenditure effects and hepatic-fat reduction not seen with semaglutide alone.

BEST FOR
Lose Fat →
Each protocol guide pairs the relevant compounds with the supplement stack that supports them and the biomarkers that show whether it’s working.
FEATURE COMPARISON
Semaglutide
Retatrutide
Full name
Semaglutide (Ozempic / Wegovy)
Retatrutide (LY-3437943)
Category
GLP-1
GLP-1
FDA status
FDA-approved as Ozempic (T2D) and Wegovy (chronic weight management).
Not FDA-approved. In Phase 3 trials. Expected FDA filing ~2026.
Half-life
~7 days
~6 days
Typical dosing
0.25 → 2.4 mg weekly (titrated over 16+ weeks)
1 → 12 mg weekly (research dosing - not FDA-approved)
Route
Subcutaneous (weekly)
Subcutaneous (weekly)
Classification
GLP-1 receptor agonist
Triple agonist (GIP + GLP-1 + glucagon receptor)
BIOMARKERS COMMONLY TRACKED
On Semaglutide
  • • HbA1c
  • • Fasting glucose
  • • ApoB
  • • Fasting insulin
  • • LFTs
  • • Weight
On Retatrutide
  • • HbA1c
  • • ApoB
  • • Fasting glucose
  • • LFTs (ALT, AST)
  • • Heart rate
  • • Weight
CALCULATOR
Semaglutide reconstitution →
CALCULATOR
Retatrutide reconstitution →
CONDITIONS USERS RESEARCH THESE FOR
Informational only - neither compound is presented as a treatment for any condition. These are contexts in which users research these compounds and discuss them with their licensed provider.
METABOLIC
Insulin Resistance
The metabolic pattern where cells become less responsive to insulin - trackable through specific biomarkers before it becomes diabetes.
METABOLIC
Metabolic Syndrome
The constellation of cardiovascular + metabolic risk factors - diagnosed clinically, tracked via a specific marker cluster.
CARDIOVASCULAR
Elevated ApoB (Cardiovascular Risk)
When the atherogenic particle count is elevated - the single most accurate cardiovascular risk lab marker.
METABOLIC
Elevated Visceral Fat
The metabolically-active abdominal fat linked to cardiovascular + insulin-resistance risk. Hard to see; visible in labs.
RELATED COMPARISONS
Semaglutide vs Tirzepatide
Tirzepatide vs Retatrutide
FREQUENTLY ASKED QUESTIONS

What is the difference between Semaglutide and Retatrutide?

Semaglutide is a GLP-1 mono-agonist, FDA-approved. Retatrutide is a triple agonist (GLP-1 + GIP + glucagon), Phase 3, not yet FDA-approved. Retatrutide's Phase 2 data showed ~24% weight reduction at 48 weeks vs semaglutide's ~15% at 68 weeks (different trials, not head-to-head). The glucagon arm of retatrutide adds energy-expenditure effects and hepatic-fat reduction not seen with semaglutide alone.

Who typically researches Semaglutide vs Retatrutide?

Users researching the investigational triple-agonist class vs established GLP-1 mono-therapy. Semaglutide (GLP-1, ~7 days, Subcutaneous (weekly)) and Retatrutide (GLP-1, ~6 days, Subcutaneous (weekly)) differ in mechanism and dosing cadence - the right choice depends on protocol goals, biomarker baseline, and provider guidance. MyProtocolStack lets you log doses and lab values for both side-by-side if you're cycling between them.

What blood markers do users track on Semaglutide or Retatrutide?

Biomarkers commonly tracked across Semaglutide and Retatrutide protocols include HbA1c, Fasting glucose, ApoB, Fasting insulin, LFTs, Weight, LFTs (ALT, AST), Heart rate. Establishing a baseline before starting and re-drawing at consistent intervals lets you measure each compound's effect against your own reference point - generic lab ranges are less informative than your personal trend over time. MyProtocolStack tracks these biomarkers in the context of whichever compound you're currently running.

Whichever you're tracking, we built the dashboard for it.

Log doses, upload labs, watch the biomarkers trend. StackAI reads your panel in context of what you're actually running.

Start tracking free →

Informational comparison only - not medical advice. Research-stage compounds discussed are not FDA-approved unless specifically noted. Any protocol decision should be made with a licensed healthcare provider.